glp 1 agonists and sglt2 inhibitors combination Combining GLP-1 Receptor in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique | Diabetes Therapy GLP1 Receptor Agonists vs SGLT2-I

doi: 10.2174/138945012798868434 [DOI] [PubMed] [Google Scholar] 21

In a population pharmacokinetic analysis of four clinical trials, the mean semaglutide plasma concentration was estimated at 15.3 nM with 0.5 mg/week of semaglutide and 30.6 nM with 1.0 mg/week of semaglutide in the blood samples collected from week 4 to week 56 of treatment (98)

GLP-1 agonists and blood pressure: A review of the evidence

Shin, J

Table 1 summarizes the RCTs that measured the weight-reducing effects and the other secondary outcomes of GLP-1RA in PCOS patients

Importantly, a substantial number of patients had multiple reasons noted for stopping (21%), underscoring the complexity of real-world medication use and the challenges patients face when using these therapies